Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO P
Post# of 341
(Total Views: 195)
Posted On: 01/10/2022 2:46:56 PM
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise
- CEO to participate in panel discussion, fireside chat focusing on psychedelics
- The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape
- CYBN is implementing a three-pillar strategy
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://nnw.fm/YqNaY).
The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled “Psychedelics: More Than Just a Trip” during the 11th annual LifeSci Partners Corporate Access Event. The two-day event is slated for Jan. 5–7, 2022, with the panel discussion scheduled for Wednesday, Jan. 5, at 10 a.m. EST. (Click here to register and access the webcast.)
In addition, Drysdale will participate in a fireside chat during the virtual three-day H.C. Wainwright Bioconnect Conference. Drysdale’s fireside chat will be available on demand beginning Jan. 10, 2022, at 7 a.m. EST. (Click here to register and access the webcast.)
Drysdale’s expertise in the psychedelics field is being recognized as Cybin continues to establish itself as a leading ethical biopharmaceutical company. The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape. To accomplish this lofty vision, Cybin is following a three-pillar strategy based on the following: novel drug-discovery platform (API modification), proprietary drug-delivery systems (R&D) and innovative treatment regimens (https://nnw.fm/f751C).
Cybin is developing new APIs through selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential. These modifications involve replacing selective hydrogens with deuterium atoms.
The company’s R&D, categorized under the proprietary drug-delivery systems, involves the development of an efficient delivery system that attempts to bypass liver metabolism with a direct path to the brain, thereby providing faster onset. The company is also looking to identify modified-release formulations with the potential to reduce side effects and control exposure, as well as providing dose control through its proprietary device platform.
Cybin’s treatment regimen is where science meets technology. Its exclusive EMBARK is a best-practices psychotherapy program designed to provide consistent therapist training and consistent psychotherapy delivery in clinical trials.
Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- CEO to participate in panel discussion, fireside chat focusing on psychedelics
- The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape
- CYBN is implementing a three-pillar strategy
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://nnw.fm/YqNaY).
The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled “Psychedelics: More Than Just a Trip” during the 11th annual LifeSci Partners Corporate Access Event. The two-day event is slated for Jan. 5–7, 2022, with the panel discussion scheduled for Wednesday, Jan. 5, at 10 a.m. EST. (Click here to register and access the webcast.)
In addition, Drysdale will participate in a fireside chat during the virtual three-day H.C. Wainwright Bioconnect Conference. Drysdale’s fireside chat will be available on demand beginning Jan. 10, 2022, at 7 a.m. EST. (Click here to register and access the webcast.)
Drysdale’s expertise in the psychedelics field is being recognized as Cybin continues to establish itself as a leading ethical biopharmaceutical company. The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape. To accomplish this lofty vision, Cybin is following a three-pillar strategy based on the following: novel drug-discovery platform (API modification), proprietary drug-delivery systems (R&D) and innovative treatment regimens (https://nnw.fm/f751C).
Cybin is developing new APIs through selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential. These modifications involve replacing selective hydrogens with deuterium atoms.
The company’s R&D, categorized under the proprietary drug-delivery systems, involves the development of an efficient delivery system that attempts to bypass liver metabolism with a direct path to the brain, thereby providing faster onset. The company is also looking to identify modified-release formulations with the potential to reduce side effects and control exposure, as well as providing dose control through its proprietary device platform.
Cybin’s treatment regimen is where science meets technology. Its exclusive EMBARK is a best-practices psychotherapy program designed to provide consistent therapist training and consistent psychotherapy delivery in clinical trials.
Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼